Jade Biosciences to Participate in Two Upcoming Investor Conferences

Core Insights - Jade Biosciences, Inc. is participating in two upcoming investor conferences to discuss its developments in autoimmune disease therapies [1][2][3] Company Overview - Jade Biosciences focuses on developing best-in-class therapies for autoimmune diseases, with its lead candidate, JADE101, targeting the cytokine APRIL for immunoglobulin A nephropathy [4] - The company plans to initiate a first-in-human clinical trial for JADE101 in the second half of 2025 [4] - Jade's pipeline includes a second candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both in preclinical development [4] - Jade was established based on assets licensed from Paragon Therapeutics, an antibody discovery engine [4] Upcoming Events - CEO Tom Frohlich and CSO Andrew King will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025 [2] - They will also take part in a fireside chat at the 2025 Stifel Biotech Summer Summit on August 13, 2025 [3] - The management team will host one-on-one investor meetings during these conferences [3]